Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]